Cerebral glioma: evaluation with methionine PET

Area of Science:

• Neuroimaging
• Oncology
• Nuclear Medicine

Background:

• Cerebral gliomas are primary brain tumors with varying grades of malignancy.
• Accurate assessment of tumor extent and grade is crucial for treatment planning and prognosis.
• Current imaging modalities like computed tomography (CT) have limitations in fully characterizing glioma extent and grade.

Purpose of the Study:

• To evaluate the utility of positron emission tomography (PET) using L-methyl-11C-methionine (C-11 methionine) in assessing the grade of malignancy and the extent of cerebral glioma.
• To compare the diagnostic performance of C-11 methionine PET with CT in delineating glioma boundaries.

Main Methods:

• The study involved 50 patients diagnosed with cerebral glioma.
• Positron emission tomography (PET) with C-11 methionine was employed to image the brain lesions.
• The accumulation and uptake rate of C-11 methionine were analyzed in relation to glioma grade.
• Findings were correlated with CT scans and confirmed by surgical intervention.

Main Results:

• High accumulation of C-11 methionine was observed in most high-grade gliomas (31/32) and a subset of low-grade gliomas (11/18).
• Significantly higher C-11 methionine uptake rates were found in high-grade gliomas compared to low-grade gliomas (P < .001).
• Methionine PET delineated the extent of cerebral glioma more accurately than CT, as confirmed by surgical findings.

Conclusions:

• C-11 methionine PET is valuable for assessing the extent of cerebral glioma.
• While C-11 methionine uptake correlates with glioma grade, differentiating malignancy grade solely based on accumulation can be challenging.
• Methionine PET offers superior delineation of tumor boundaries compared to CT.